Skip to content
value.today

Amunix Pharmaceuticals, Inc.

Total raised
$201 M
2 rounds on record
Latest round
$117 M
Feb 2021
First round on record
Feb 2020
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Amunix Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2021$117 MNo. 2$50 to $250 million

Amunix Pharmaceuticals, Inc.: Raise no. 2, Feb 2021

Investors in this round

28 investors had bought by the notice of Mar 9, 2021: 28 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$117 M of $117 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Angie You · Executive Officer, Director
  • Volker Schellenberger · Executive Officer
  • David Hirsch · Director
  • James Brush · Director
  • James Topper · Director
  • Otello Stampacchia · Director
  • Richard Heyman · Director
  • Trisha Millican · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Angie You, Ph.D., Ceo. Source: SEC Form D, newest notice filed Mar 9, 2021. Read the notice at the SEC.

equitySEC
Feb 2020$84 MNo. 1$50 to $250 million

Amunix Pharmaceuticals, Inc.: Raise no. 1, Feb 2020

Investors in this round

21 investors had bought by the notice of Mar 12, 2020: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$84 M of $84 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Angie You · Executive Officer, Director
  • Volker Schellenberger · Executive Officer
  • David Hirsch · Director
  • James Brush · Director
  • James Topper · Director
  • Otello Stampacchia · Director
  • Richard Heyman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes conversion of principal and accrued interest under converted notes.”

Signed by Angie You, Ph.D., Ceo. Source: SEC Form D, newest notice filed Mar 12, 2020. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Amunix Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2021).

    SEC Form D · Mar 2021

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Mar 2021

That is all the official record says: Amunix Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Amunix Pharmaceuticals, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 28 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Amunix Pharmaceuticals, Inc.
NameRoleNamed in
Angie YouExecutive officerMar 2021
Volker SchellenbergerExecutive officerMar 2021
Angie YouDirectorMar 2021
David HirschDirectorMar 2021
James BrushDirectorMar 2021
James TopperDirectorMar 2021
Otello StampacchiaDirectorMar 2021
Richard HeymanDirectorMar 2021
Trisha MillicanDirectorMar 2021